Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 3Completed 1

Sponsor Class

NIH 6OTHER 4

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Head & Neck 4Endocrine 4

Conditions

Prostatic Neoplasms 142Breast Neoplasms 97Lung Neoplasms 72Brain Neoplasms 67Glioblastoma 59Carcinoma, Non-Small-Cell Lung 54Glioma 52Pancreatic Neoplasms 39Neoplasms 39Neoplasm Metastasis 36Colorectal Neoplasms 31Carcinoma, Hepatocellular 30Lymphoma, Large B-Cell, Diffuse 27Carcinoma, Renal Cell 27Multiple Myeloma 26Squamous Cell Carcinoma of Head and Neck 25Rectal Neoplasms 21Melanoma 21Ovarian Neoplasms 20Astrocytoma 20Urinary Bladder Neoplasms 18Lymphoma, Follicular 18Uterine Cervical Neoplasms 17Colonic Neoplasms 17Head and Neck Neoplasms 16Lymphoma 15Esophageal Neoplasms 15Sarcoma 14Lymphoma, Mantle-Cell 14Lymphoma, B-Cell 14

Interventions

Iodine-131 5dabrafenib 4Vemurafenib 4Magnetic Resonance Spectroscopy 4trametinib 3lenvatinib 3Transurethral Resection of Prostate 3Thyrotropin Alfa 3Thyroidectomy 3selpercatinib 2cobimetinib 2X-Rays 2Thyroid (USP) 2Surgical Procedures, Operative 2Sunitinib 2Specimen Handling 2Radiofrequency Ablation 2Interviews as Topic 2vandetanib 1tremelimumab 1spartalizumab 1pembrolizumab 1pazopanib 1durvalumab 1delta 24-sterol reductase 1copanlisib 1cabozantinib 1Whole Body Imaging 1Thyrotropin 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Thyroid Cancer, Papillary × Magnetic Resonance Spectroscopy × Clear all
NCT06959641 2026-05-22

XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer

Northwestern University

Phase 2 Recruiting
33 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT05575440 2026-02-27

Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer

Mayo Clinic

Recruiting
24 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT06440850 2026-02-02

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

City of Hope Medical Center

Phase 2 Recruiting
21 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT02178345 2021-12-08

Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer

Memorial Sloan Kettering Cancer Center

Completed
123 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡